Table 1.
Patient characteristics.
| Distribution | Missing, n (%) | |
|---|---|---|
| Age at diagnosis, median (range) | 56 (35–68) | 0 |
| Tumor grade, n (%) | 312 | 1 (0.3) |
| 1 | 98 (31.4) | |
| 2 | 132 (42.3) | |
| 3 | 82 (26.3) | |
| Molecular subgroup, n (%) | 312 | 1 (0.3) |
| Luminal A | 194 (62.2) | |
| Luminal B | 63 (20.2) | |
| HER2 + | 15 (4.8) | |
| Basal-like | 40 (12.8) | |
| Tumor diameter in millimeters, median (range) | 16 (1–92) | 0 |
| Surgery, n (%) | 313 | 0 |
| Lumpectomy | 213 (68.1) | |
| Mastectomy | 100 (32.0) | |
| Lymph node metastasis, n (%) | 311 | 2 (0.6) |
| Yes | 94 (30.2) | |
| No | 217 (69.8) | |
| Distant metastasisa, n (%) | 310 | 3 (1.0) |
| Yes | 34 (11.0) | |
| No | 276 (89.0) | |
| Relapse, n (%) | 311 | 2 (0.6) |
| Yes | 25 (8.0) | |
| No | 286 (92.0) | |
| ER positive, n (%) | 313 | 0 |
| Yes | 253 (80.8) | |
| No | 60 (19.2) | |
| PR positive, n (%) | 303 | 10 (3.2) |
| Yes | 203 (67.0) | |
| No | 100 (33.0) | |
| HER2 positive, n (%) | 312 | 1 (0.3) |
| Yes | 38 (12.2) | |
| No | 274 (87.8) | |
| Menopausal status at diagnosis | 313 | 0 |
| Post-menopausal | 219 (70.0) | |
| Pre-menopausal | 94 (30.0) | |
| Age at menarche, mean (SD) | 13.0 (1.3) | 4 (1.3) |
| Parity | 313 | 0 |
| 0 | 32 (10.2) | |
| ≥ 1 | 281 (89.8) | |
| Body mass index, n (%) | 306 | 7 (2.2) |
| < 25 | 182 (59.5) | |
| 25–30 | 95 (31.1) | |
| > 30 | 29 (9.5) | |
| Smoking status at first questionnaire, n (%) | 312 | 2 (0.6) |
| Never | 108 (34.6) | |
| Ever | 204 (65.4) |
ER estrogen receptor, HER2 human epidermal growth factor receptor 2, PR progesterone receptor, IQR interquartile range, SD standard deviation.
aDistant metastasis at any time point.